---
layout: minimal-medicine
title: Remifentanil
---

# Remifentanil
### Generic Name
Remifentanil

### Usage

Remifentanil is a potent opioid analgesic primarily used for managing pain during surgery and in the immediate postoperative period.  Its rapid onset and extremely short duration of action make it particularly suitable for situations requiring precise control of analgesia, such as during general anesthesia, monitored anesthesia care (MAC), and in intensive care units (ICUs).  It's administered intravenously (IV) as a continuous infusion or as intermittent boluses. While primarily used for anesthesia and analgesia in adults, it also has off-label uses in pediatrics under specific circumstances and with close monitoring.

### Dosage

**Adult Dosage:**  Dosage is highly individualized and depends on the patient's weight, the procedure, and the desired level of analgesia or anesthesia.  It's crucial that administration is only by healthcare professionals experienced in managing anesthesia and analgesia.  The following are examples and should not be interpreted as universally applicable:

* **Induction of Anesthesia:**  0.5-1 mcg/kg/min IV continuous infusion.  Higher initial doses (1 mcg/kg) may be given over 30-60 seconds before endotracheal intubation if needed within 8 minutes.

* **Maintenance of Anesthesia:**  The infusion rate is titrated to the patient's response, typically ranging from 0.1 to 2 mcg/kg/min.  This rate will be adjusted based on factors including the use of other anesthetic agents (e.g., nitrous oxide, isoflurane, propofol). Supplemental bolus doses may be given.

* **Postoperative Analgesia (Immediate Postoperative Period):** Typically 0.1 mcg/kg/min IV continuous infusion, titrated downward as needed.  Bolus doses are generally not recommended in this setting.

* **Monitored Anesthesia Care (MAC):**  Dosage varies greatly depending on the procedure and other medication used, utilizing both boluses and infusions.

**Pediatric Dosage:** Pediatric dosing is complex and highly individualized.  It is crucial that pediatric administration only takes place under the supervision of anesthesiologists or other medical practitioners experienced in pediatric anesthesia.  Use in children and adolescents is mostly off-label,  with dosages varying greatly depending on the specific application (anesthesia, postoperative pain management, procedural sedation) and patient factors.  Intranasal administration (using a parenteral formulation) has been used in children under specific circumstances. Consult the relevant prescribing information for details on pediatric dosing regimens.

**Dosage Adjustments:** Dosage adjustments are generally not necessary for renal or hepatic impairment, but obese patients should have their initial dose based on ideal body weight (IBW).

**Administration:** Remifentanil is administered intravenously (IV).  Continuous infusions require the use of an infusion pump.  Careful attention needs to be paid to properly clearing IV lines after use to prevent residual effects.

### Side Effects

**Common Side Effects:**

* Hypotension
* Nausea and vomiting
* Respiratory depression (a serious side effect)
* Headache
* Pruritus (itching)
* Muscle rigidity

**Less Common but Serious Side Effects:**

* Bradycardia
* Apnea (cessation of breathing)
* Hypoxia (low blood oxygen)
* Chest pain
* Allergic reactions (rare)

**Note:**  This is not an exhaustive list.  Any unusual or concerning side effects should be reported to a healthcare provider immediately.

### How it Works

Remifentanil is a mu-opioid receptor agonist. This means it binds to specific opioid receptors in the central nervous system (brain and spinal cord), reducing pain signals and promoting analgesia.  Its rapid metabolism accounts for its brief duration of action.

### Precautions

* **Contraindications:** Remifentanil is contraindicated in patients with known hypersensitivity, those with certain respiratory or cardiovascular conditions (e.g., severe respiratory depression, severe COPD), and those with a mechanical gastrointestinal obstruction.  It should not be administered intrathecally or epidurally.  Concurrent use with MAO inhibitors is also contraindicated.

* **Interactions:** Remifentanil can interact with other medications, particularly other CNS depressants (e.g., benzodiazepines, other opioids, barbiturates).  These interactions can increase the risk of respiratory depression.  It can also interact with blood pressure-lowering drugs.

* **Warnings:**  There is a boxed warning regarding the potential for addiction, abuse, and misuse.  Special caution is needed in patients with: impaired respiratory function, heart disease, liver or kidney problems, hypovolemia, or those who are obese or elderly.  Close monitoring is essential.  Pregnant and breastfeeding women should discuss the risks and benefits with their healthcare providers before using Remifentanil.

### FAQs

* **Q: How long does Remifentanil last?** A:  Remifentanil's effect is extremely short-lived due to rapid metabolism, typically lasting only minutes after infusion is stopped.

* **Q: Can I drive after receiving Remifentanil?** A:  No. Remifentanil can cause drowsiness, dizziness, and impaired judgment. Do not drive or operate machinery until fully recovered.

* **Q: How is Remifentanil stored?** A:  Refer to the product labeling for specific storage instructions, but generally it should be stored according to the manufacturer's recommendations to maintain its efficacy and safety.

* **Q: What should I do if I experience side effects?** A:  Report any unusual or concerning side effects to your healthcare provider immediately.

**Disclaimer:** This information is for general knowledge and does not constitute medical advice.  Always consult with a healthcare professional for diagnosis, treatment, and any questions regarding your medical condition or medication.  This information is based on publicly available data and may not include all possible information about this medication.  Always refer to the official prescribing information for the most up-to-date and complete details.
